Press Releases May 27, 2026 08:30 AM

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

Lantheus Holdings to Present at William Blair 46th Annual Growth Stock Conference

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
LNTH

Lantheus Holdings, a leading radiopharmaceutical company, announced its participation in the William Blair 46th Annual Growth Stock Conference, with Vice President John Wiggins to take part in a fireside chat. The company highlighted its longstanding presence in the radiopharmaceutical field and commitment to improving patient outcomes through innovative science.

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
LNTH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lantheus specializes in radiopharmaceuticals aimed at aiding disease detection and treatment.
  • Company leadership will present and engage in discussions at a prominent growth stock conference.
  • Lantheus has a global presence with a 70-year history in the healthcare sector.

BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.

To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]

Melissa Downs
Executive Director, External Communications
646-975-2533
[email protected]


Risks

  • The announcement is a standard corporate presentation and may not immediately impact financial performance.
  • Potential market uncertainties in the healthcare and biotechnology sectors could affect investor response.
  • Competition and regulatory challenges in the radiopharmaceutical industry remain ongoing risks.

More from Press Releases

FTAI Aviation and AEI Announce Strategic Collaboration to Meet Growing Demand for Boeing 737-800 Freighters Jul 7, 2026 Parsons Awarded Program and Construction Management Contract for Lusail Development in Qatar Jul 7, 2026 VEON to Report 2Q26 Results on July 31, 2026 Jul 7, 2026 Comstock Metals Integrates and Automates Front Stages of Industry-scale Production Jul 7, 2026 Titan Confirms District-Wide Germanium Enrichment as Critical Mineral Push Expands at Empire State Mines Jul 7, 2026